Literature DB >> 22665579

Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort.

Veronica Wendy Setiawan1, Rayna K Matsuno, Galina Lurie, Lynne R Wilkens, Michael E Carney, Brian E Henderson, Laurence N Kolonel, Marc T Goodman.   

Abstract

BACKGROUND: Chronic inflammation may play an etiologic role in ovarian and endometrial cancer, and it is hypothesized that nonsteroidal anti-inflammatory drugs (NSAID) decrease the risk of developing these malignancies. No prospective study with a large multiethnic population has explored this hypothesis.
METHODS: We investigated whether NSAID use was associated with risks of ovarian and endometrial cancer in the Multiethnic Cohort Study. Medication use of at least twice a week for ≥1 month was assessed at baseline. Multivariable relative risks (RR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models.
RESULTS: During 13.3 years of follow-up, 275 ovarian and 620 endometrial incident cases were identified among approximately 64,000 women included in this analysis (16.5% African Americans, 30.8% Japanese, 7.7% Native Hawaiians, 18.9%, Latinas, and 26.0% whites). The RR (95% CI) for ovarian cancer associated with aspirin, non-aspirin NSAIDs, and acetaminophen were 0.87 (0.68-1.14), 0.97 (0.74-1.26), and 0.86 (0.67-1.12), respectively. The RR (95% CI) for endometrial cancer associated with aspirin, non-aspirin NSAIDs, and acetaminophen were 0.93 (0.79-1.10), 0.88 (0.74-1.05), and 0.96 (0.81-1.13), respectively. No heterogeneity across ethnic groups (P ≥ 0.29) or dose-response relation with increased duration of use (P(trend) ≥ 0.16) was observed. The results did not differ by tumor histology.
CONCLUSIONS: We found no compelling evidence to support an association between the use of NSAIDs and risk of ovarian and endometrial cancers in a multiethnic population. IMPACT: It is unlikely that NSAID is involved in the etiology of endometrial and ovarian cancer. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665579      PMCID: PMC3436975          DOI: 10.1158/1055-9965.EPI-12-0390-T

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  46 in total

1.  Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.

Authors:  Stefanos Bonovas; Kalitsa Filioussi; Nikolaos M Sitaras
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

2.  Nonsteroidal antiinflammatory drugs and progestins synergistically enhance cell death in ovarian epithelial cells.

Authors:  Gustavo C Rodriguez; Jane M Turbov; Andrew Berchuck; M Sharon Stack; Jean A Hurteau; Larry G Thaete; Catherine P Barry
Journal:  Am J Obstet Gynecol       Date:  2011-11-25       Impact factor: 8.661

3.  C-reactive protein concentrations and subsequent ovarian cancer risk.

Authors:  Meghan A McSorley; Anthony J Alberg; Diane S Allen; Naomi E Allen; Louise A Brinton; Joanne F Dorgan; Michael Pollak; Yuzhen Tao; Kathy J Helzlsouer
Journal:  Obstet Gynecol       Date:  2007-04       Impact factor: 7.661

4.  Aspirin and ovarian cancer: an Italian case-control study.

Authors:  A Tavani; S Gallus; C La Vecchia; E Conti; M Montella; S Franceschi
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

5.  Pelvic inflammatory disease and the risk of epithelial ovarian cancer.

Authors:  H A Risch; G R Howe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Jul-Aug       Impact factor: 4.254

6.  Medication use and risk of ovarian carcinoma: a prospective study.

Authors:  James V Lacey; Mark E Sherman; Patricia Hartge; Arthur Schatzkin; Catherine Schairer
Journal:  Int J Cancer       Date:  2004-01-10       Impact factor: 7.396

7.  Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

Authors:  Melissa A Merritt; Adèle C Green; Christina M Nagle; Penelope M Webb
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

8.  Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.

Authors:  Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2009-04-02       Impact factor: 4.897

9.  Endometriosis and ovarian cancer: a systematic review.

Authors:  Ahmad Sayasneh; Dimitris Tsivos; Robin Crawford
Journal:  ISRN Obstet Gynecol       Date:  2011-07-15

10.  Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.

Authors:  H T Sørensen; S Friis; B Nørgård; L Mellemkjaer; W J Blot; J K McLaughlin; A Ekbom; J A Baron
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more
  20 in total

1.  PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.

Authors:  Hannah P Yang; Alan Meeker; Richard Guido; Marc J Gunter; Gloria S Huang; Patricia Luhn; Lori d'Ambrosio; Nicolas Wentzensen; Mark E Sherman
Journal:  Cancer Causes Control       Date:  2015-09-16       Impact factor: 2.506

2.  Ovarian Cancer in Women of African Ancestry (OCWAA) consortium: a resource of harmonized data from eight epidemiologic studies of African American and white women.

Authors:  Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2019-06-24       Impact factor: 2.506

3.  Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.

Authors:  Theodore M Brasky; Ashley S Felix; David E Cohn; D Scott McMeekin; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Kay J Park; Shamshad Ali; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

Review 4.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice.

Authors:  Chun-Xiao Xu; Hong-Hong Zhu; Yi-Min Zhu
Journal:  World J Diabetes       Date:  2014-06-15

5.  Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.

Authors:  Mollie E Barnard; Elizabeth M Poole; Gary C Curhan; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

6.  Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Kirsten B Moysich; David E Cohn; Emily White
Journal:  Gynecol Oncol       Date:  2012-10-09       Impact factor: 5.482

Review 7.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

8.  Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.

Authors:  Lauren M Hurwitz; Paul F Pinsky; Wen-Yi Huang; Neal D Freedman; Britton Trabert
Journal:  Gynecol Oncol       Date:  2020-09-10       Impact factor: 5.482

9.  Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.

Authors:  Britton Trabert; Elizabeth M Poole; Emily White; Kala Visvanathan; Hans-Olov Adami; Garnet L Anderson; Theodore M Brasky; Louise A Brinton; Renee T Fortner; Mia Gaudet; Patricia Hartge; Judith Hoffman-Bolton; Michael Jones; James V Lacey; Susanna C Larsson; Gerardo G Mackenzie; Leo J Schouten; Dale P Sandler; Katie O'Brien; Alpa V Patel; Ulrike Peters; Anna Prizment; Kim Robien; V Wendy Setiawan; Anthony Swerdlow; Piet A van den Brandt; Elisabete Weiderpass; Lynne R Wilkens; Alicja Wolk; Nicolas Wentzensen; Shelley S Tworoger
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

10.  Dampening the fire to prevent surgery- and chemotherapy-induced metastasis.

Authors:  Esra Güç; Jeffrey W Pollard
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.